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Abstract: The global HIV response is leaving children and
adolescents behind. Because of a paucity of studies on treatment
and care models for these age groups, there are gaps in our
understanding of how best to implement services to improve their
health outcomes. Without this evidence, policymakers are left to
extrapolate from adult studies, which may not be appropriate, and
can lead to inefﬁciencies in service delivery, hampered uptake, and
ineffective mechanisms to support optimal outcomes. Implementa-
tion science research seeks to investigate how interventions known
to be efﬁcacious in study settings are, or are not, routinely
implemented within real-world programmes. Effective implementa-
tion science research must be a collaborative effort between
government, funding agencies, investigators, and implementers,
each playing a key role. Successful implementation science research
in children and adolescents requires clearer policies about age of
consent for services and research that conform to ethical standards
but allow for rational modiﬁcations. Implementation research in
these age groups also necessitates age-appropriate consultation and
engagement of children, adolescents, and their caregivers. Finally,
resource, systems, technology, and training must be prioritized to
improve the availability and quality of age-/sex-disaggregated data.
Implementation science has a clear role to play in facilitating under-
standing of how the multiple complex barriers to HIV services for
children and adolescents prevent effective interventions from reaching
more children and adolescents living with HIV, and is well positioned to
redress gaps in the HIV response for these age groups. This is truer now
more than ever, with urgent and ambitious 2020 global targets on the
horizon and insufﬁcient progress in these age groups to date.
Key Words: children, adolescents, HIV, implementation science,
research
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INTRODUCTION
The global HIV response is leaving children and
adolescents behind. Antiretroviral therapy (ART) for children
and adolescents is no less efﬁcacious than for adults, yet
children and adolescents continue to suffer a disproportionate
burden of HIV morbidity and mortality. Children younger
than 15 years of age account for 6% of the total people living
with HIV globally but 11% of AIDS-related deaths.1 Since
2010, AIDS-related deaths among adolescents have decreased
by just 5%.2 In 2015, AIDS was the fourth most frequent
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cause of death among girls aged 10–14 years globally, and the
fourth most common cause of death among all 10 to 19-year-
olds in African low- and middle-income countries, with an
estimated cause-speciﬁc mortality rate of 17.2 per 100,000
adolescents per year.3
Children and adolescents continue to be underserved by
services across the HIV treatment cascade.4 Of the 2.1 million
children younger than 15 years living with HIV, only 43%
have access to ART, compared with 54% of adults aged 15
years and older.5 Given the rapid disease progression leading
to high mortality rates in HIV-positive children,6 low early
infant diagnosis coverage and linkage to care rates continue to
pose signiﬁcant threats to infant, child and adolescent health,
and survival.7 Despite improvements in pediatric treatment
options, children younger than 15 years continue to have
lower viral suppression rates compared with adults aged 15
years and older.8 Complicating treatment, children face
challenges arising from previous drug exposure during
inadequate prevention of mother-to-child transmission, in
addition to receiving suboptimal ART formulations them-
selves which introduce risk of overdosing or underdosing.9 A
systematic review in resource-limited settings showed that
5–29% of children who initiated ART during the ﬁrst decade
of life were either lost-to-follow-up or deceased by 12
months.10 Although HIV testing is the entry point to the
HIV treatment, care and support cascade, only 33% of
adolescent girls and 20% of adolescent boys in Africa report
having ever been tested for HIV.11
Treatment adherence and retention of children and
adolescents depend on caregivers’ ability, willingness,
and resources to support their care. Regimens for infants
and children are often poorly palatable and require compli-
cated administration techniques, higher pill burden, and
frequent dosing changes to accommodate growth, complicat-
ing the prescribing and administration of medicine, as well as
adherence. Adolescents with HIV face their own challenges
arising from their evolving growth and development—they
need to transition from pediatric to adult care, seek care
independently of a caregiver, balance demands on their time
for school and clinic appointments, and build resilience
against the stigma and discrimination they will likely
experience from their peers, in their schools and in their
communities. The operational challenges for both children
and adolescents present unique barriers to treatment feasibil-
ity and acceptability compared with adults, requiring tailored
evidence to inform policy and programming decisions.
Without such evidence, policymakers are left to extrapolate
from adult studies, which may not be appropriate and can lead
to inefﬁciencies in service delivery, hampered uptake, and
ineffective mechanisms to support optimal outcomes in these
vulnerable populations.
The importance of implementation science research to
investigate, within real-world programmes, how interventions
that have been shown to be effective in research settings
should be implemented, is being increasingly recognized.
This is supported by the recent priority-setting process
undertaken by the World Health Organization (WHO) and
Collaborative Initiative for Pediatric HIV Education and
Research (CIPHER) to develop Global Research Agendas
on Children and Adolescents Living with HIV, where
implementation came out strongly as an overarching issue,
with questions across the 3 thematic areas of testing,
treatment, and service delivery for both pediatric and
adolescent populations.12,13 This article summarizes key
elements identiﬁed during the development of the research
agenda related to conducting implementation science research
in children and adolescents living with HIV, examines where
we are with implementation science for children and adoles-
cents living with HIV today, and identiﬁes what challenges
persist and how they differ for the 2 populations. Potential
barriers to conducting implementation science research for
children and adolescents and what is needed for success are
also discussed.
USING IMPLEMENTATION SCIENCE WHERE IT
IS NEEDED MOST
Although global indicators suggest inferior outcomes in
children and adolescents when compared with adults, and that
services face particularly severe challenges in providing
access for these age groups, systematic reviews14,15 reveal
a paucity of studies in low- and middle-income countries
evaluating effective treatment and care models that address
the unique needs of children and adolescents. Although ART
efﬁcacy trials in children and adolescents and pediatric cohort
data analysis do occur—albeit to a lesser extent than in adults
—there are gaps in our understanding of how best to
implement routine services for children and adolescents to
improve their health outcomes. To date, most implementation
studies focus on adult care16; however, their results usually do
not directly translate to addressing the particular challenges
faced by children and adolescents.
Randomized controlled trials are regarded as the “gold
standard” in demonstrating efﬁcacy, but exert artiﬁcial control
over patient, intervention, and setting, none of which are
reproducible in routine programs. Although an important part
of the investigative toolkit, traditional clinical study design
cannot address the translational elements necessary for
successful health interventions in real-world settings and as
such should not be used to the exclusion of other approaches.
Implementing efﬁcacious pediatric and adolescent interven-
tions in routine programs requires services to overcome
barriers that also require investigation as part of policy and
program planning. Many of these barriers are speciﬁc to
developmental stage and differ between the 2 age groups.
Factors such as caregiver support, regimen complexity,
service setting, and role of peers and stigma may impact
treatment success differently by age. Unless efﬁcacy trials are
supplemented by implementation studies in speciﬁc age
ranges, our understanding of the true effectiveness of pro-
posed interventions in routine programs will be very limited.
Implementation science research seeks generalizable
knowledge as to how interventions that are known to be
efﬁcacious in study settings are, should, or should not be
implemented within real-world programs.17 It aims to
improve the quality and effectiveness of health services by
identifying, quantifying, and understanding the barriers to,
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and enablers of, implementation of evidence-
based interventions.
Implementation science seeks to understand how both
successes and failures happen, and therefore, emphasizes
conceptualization and reporting of implementation strategies
as well as implementation outcomes.18,19 The utility of
implementation science ﬁndings and its ability to identify
interventions that not only work but also can be widely
adopted into complex delivery ecosystems, means that it can
be of great value in health planning, delivery,
and policymaking.
The priorities of implementation science are well suited
to investigating the multiple complex barriers to HIV services
for children and adolescents. Implementation science has
a clear role to play in understanding how these barriers
prevent effective interventions from reaching more children
and adolescents living with HIV and is well positioned to
redress gaps in the HIV response for these age groups. This is
truer now more than ever, with urgent and ambitious 2020
global targets on the horizon and insufﬁcient progress in these
age groups to date.
WHAT QUESTIONS CAN IMPLEMENTATION SCI-
ENCE ANSWER FOR PEDIATRIC AND ADOLESCENT
HIV TESTING, TREATMENT, AND
CARE PROGRAMS?
In 2017, the WHO and Collaborative Initiative for
Pediatric HIV Education and Research (CIPHER) led a prior-
ity-setting process based on the Child Health and Nutrition
Research Initiative (CHNRI) methodology21 to identify and
score key research questions across HIV testing, treatment,
and service delivery based on answerability, impact, imple-
mentation, and equity. The exercise resulted in a priority
research agenda for child and adolescent HIV testing,
treatment, and care aimed at informing global policy and
improving patient outcomes.12,13
Priority questions were divided into 3 categories: those
relating to testing, treatment, and service delivery, and
classiﬁed according to research type (development, discovery,
description, and delivery). Of the 51 total pediatric questions
and 61 total adolescent questions, 10 and 13, respectively,
were classiﬁed as delivery research questions. For children,
the highest proportion and total number of delivery questions
were included in the testing category (n = 6/16). Similarly, for
adolescents, the highest proportion of delivery questions was
also in the testing category (n = 5/12), with 3 of those ranking
in the top 10 questions in this age group. The highest total
number of delivery questions were in the HIV-positive
adolescent service delivery category (n = 8/32), the area
accounting for over half of the total number of questions
related to adolescents. Addressing these delivery-related
questions aligns best with an implementation science
approach given that priority questions focus on determining
effective strategies, interventions, and models to address
barriers to treatment and positive health outcomes.
IMPRACTICAL OR IMPERATIVE?
Despite the clear need for implementation science
research for children and adolescents with HIV, the number
of published implementation research studies in this ﬁeld
remains limited. This is both an indication and result of
insufﬁcient global attention on the pediatric and adolescent
HIV epidemic. But in addition, implementation science in
these age groups presents challenges to researchers and
programmers, which must be overcome.
BUILDING PARTNERSHIPS ACROSS THE DIVIDE
Service delivery and research tend to be siloed, with
different funding streams, implementers, management struc-
tures, factors affecting career advancement, and measures of
success. Although this is not a challenge speciﬁc to the
pediatric and adolescent HIV response, it nevertheless creates
one of the biggest hurdles to implementation science research
in these age groups and must be addressed. Implementation
science requires these fractured pieces to come together,
through collaboration and alignment of priorities and time-
lines. Effective implementation science research must be
a collaborative effort between government, funding agencies,
investigators, and implementers, each playing a key role.
Ministries of Health must be provided with the opportunity to
contribute to implementation research priorities and to steer
the process in country, keeping other stakeholders actively
engaged and involved. Evidence emerging from this research
should form the basis for policymaking, strategy develop-
ment, and program implementation. Funding agencies must
prioritize implementation science research and provide fund-
ing opportunities that align with global and national
research priorities.
To undertake implementation research within service
delivery settings, investigators are required to ensure rigor
within the complexity of prevailing health infrastructure,
approval processes and program timelines, cognizant of the
existing workloads of health providers, service delivery
protocols, health information systems, and targets. Similarly,
service implementers are expected to move beyond data
compliance to prioritizing the value that evidence can bring to
program planning and policy. To achieve this, relationships
between investigators and implementers must be character-
ized by trust and mutual respect. Each has a unique role to
play from conception of the research question to dissemina-
tion of results, and this must be recognized in deﬁned roles
and in the allocation of any external funding for the
implementation research. Because implementation science
inherently values local relevance and context, implementation
science research questions are more effectively conceptual-
ized when informed by collaborations between researchers,
implementers, and communities. Investigators may need to
support implementers to ensure that program data and the
lessons learned in service delivery can be shared in a way that
allows for meaningful and useful analysis, interpretation,
and application.
Successful implementation research requires imple-
menters to expose suboptimal delivery to researchers, trust
them enough to allow them to explore deﬁciencies within the
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delivery system and to identify barriers to effective pro-
gramming. Developing these types of relationships takes
effort, usually across long-term collaborations, and is rela-
tively rare. Both parties must be willing to invest in
cultivating these relationships and appreciate the distinct
constraints under which each is working. Without this
commitment, implementers may contend with researchers
who fail to understand their context, and researchers may face
disinterest and resistance.
Although adapting to a perspective that includes
implementation science requires unprecedented interdisciplin-
ary partnership, cooperation, and joint responsibility,
research-based practice (or practice-based research) presents
a unique opportunity to leverage existing program efforts and
resources to improve the quality of services.
OVERCOMING ETHICAL AND
REGULATORY HURDLES
Speciﬁc to implementation research in children and
adolescents, ethical and regulatory issues pertaining both to
age of consent for accessing services, as well as for
participating in research, pose serious barriers. Minor assent
and parental/guardian consent to research participation are
generally required, which may be challenging depending on
availability or interest of the parent/guardian to provide
consent. In adolescence, the minor may be reluctant to
disclose their HIV status and participation in a study to their
parent/guardian. Multicountry study design adds further
complexity to implementation research because age of
consent to services and research both vary across countries.
In addition, because children and adolescents are considered
vulnerable populations, implementation research in these age
groups is subject to greater scrutiny in ethical and
regulatory processes.
These facts may result in investigators limiting their
research in pediatric and adolescent populations to avoid this
complexity or these challenges in obtaining consent, such that
enrollment numbers of these countries and age groups are
insufﬁcient to draw conclusive age-/sex-speciﬁc results.
Indeed, the very mechanisms that were instituted to protect
the rights and welfare of children and adolescents have
created real or perceived barriers to identifying and imple-
menting effective services to support them. To overcome
challenges related to consent for service delivery and research
with minors, we need to advocate for policies at national level
that conform to ethical standards but allow for rational
modiﬁcations to informed consent procedures to facilitate
access to these hard-to-reach age groups, both for the delivery
of services and for their inclusion within implementation
science research and other studies.
MEANINGFULLY INVOLVING CHILDREN,
ADOLESCENTS, AND CAREGIVERS
Implementation research in children and adolescents
necessitates age-appropriate consultation and engagement
with children, adolescents, and their caregivers. With increas-
ing age, clients should be partners whose perspectives
are valued. Adolescents in particular should share in devel-
oping the research agenda and afforded opportunity to
identify priorities and reﬂect on results. With greater equity
in the research-participant and provider-patient relationships,
the viewpoints and experiences of those engaging with the
intervention are leveraged and assimilated into emerging
evidence. In the case of infants and younger children, this
process requires greater deliberation but should not be
abandoned, with the caregiver fully engaged. Diverse meth-
ods of facilitating participation across the age spectrum are
available22 and include visual methods, storytelling, repre-
sentation of young people on institutional review boards, and
young people being involved as peer researchers,
for example.
DISAGGREGATING DATA
Earlier sections have shown that children and adoles-
cents living with HIV have poorer adherence and retention in
care, and suffer from worse treatment outcomes than adults.
They share many barriers with adults such as stigma and
discrimination and ﬁnancial and time constraints, but they
also face unique challenges, such as technical requirements
for infant HIV testing, rapid growth and changing formula-
tions/dosages, the level of health worker skill required to
respond effectively to their evolving capacities, and the
transition between pediatric and adult care.
The rapid physical, cognitive, and social changes that
occur across this age group mean that children and adoles-
cents experience a wide variety of individual, family,
community, and systems barriers to care. Implementation
science research will often primarily depend on routinely
collected data. However, despite frequent calls for age- and
sex-disaggregated data, these are rarely available from routine
programs with sufﬁcient granularity to be useful for studying
the particular barriers, and the effectiveness of programmatic
changes to overcome these barriers, among children and
adolescents. As a result, implementation research across these
age groups has often required detailed age-speciﬁc
studies. These are onerous in requiring large subsamples
because the implementation barriers for an infant differ from
those of a 18-year-old, for example, and the requirements for
an 18-year-old young woman can differ from those of an 18-
year-old young man. To improve the availability of age-/sex-
disaggregated data and their quality, adequate resource
allocation, systems development that makes use of appropri-
ate technology, and training need to be prioritized. Further-
more, as we progress into an era of big data and public
accessibility, policymakers should begin to develop an
agenda for standardizing indicators, deidentiﬁcation of data
and developing a regional or centralized data hub that can be
used by programmers and policymakers to inform high-
level decision-making.
CONCLUSIONS
With super-fast-track targets rapidly approaching,23
efforts to expand and improve the identiﬁcation and treatment
of children and adolescents living with HIV must be
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accelerated. The research agenda must also be fast-tracked to
focus on useful, relevant investigations in diverse real-world
practice. Without implementation science research to explore
the speciﬁc barriers to effective treatment for children and
adolescents living with HIV, progress is likely to stall.
Implementation science cannot be allowed to lag behind in
one of the populations that most requires its results.
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